A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma

Status:
Completed

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

This was a 3-cohort, open-label study of vismodegib (GDC-0449) in new (non-recurrent) operable basal cell carcinoma of the nodular subtype.

Phase 2

Genentech, Inc.